About Mirxes
Mirxes is a company based in Singapore (Singapore) founded in 2014.. Mirxes has raised $254 million across 5 funding rounds from investors including Mitsui & Co., Charoen Pokphand Group and EDBI. The company has 352 employees as of December 31, 2024. Mirxes offers products and services including GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite. Mirxes operates in a competitive market with competitors including UDX and Liquid Mine, among others.
- Headquarter Singapore, Singapore
- Employees 352 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mirxes Holding Company Limited
-
Annual Revenue
$20.38 M (USD)-16.41as on Dec 31, 2024
-
Net Profit
$-92.76 M (USD)-32.93as on Dec 31, 2024
-
EBITDA
$-63.98 M (USD)-35.01as on Dec 31, 2024
-
Total Equity Funding
$254 M (USD)
in 5 rounds
-
Latest Funding Round
$50 M (USD), Series D
Jul 26, 2023
-
Investors
Mitsui & Co.
& 11 more
-
Employee Count
352
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mirxes
Mirxes is a publicly listed company on the HKEX with ticker symbol 2629 in Hong Kong, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mirxes
Mirxes offers a comprehensive portfolio of products and services, including GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Blood-based test for early gastric cancer detection
Test for early lung cancer identification
Diagnostic panel for syndromic infectious disease testing
Tool for cancer treatment selection and sequencing
Platform for miRNA knowledge and research applications
Unlock access to complete
Unlock access to complete
Funding Insights of Mirxes
Mirxes has successfully raised a total of $254M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $50 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series D — $50.0M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Series D - Mirxes | Valuation | Mitsui | |
| Oct, 2021 | Amount | Series C - Mirxes | Valuation |
investors |
|
| Jul, 2021 | Amount | Series C - Mirxes | Valuation | Rock Springs Capital , Charoen Pokphand Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mirxes
Mirxes has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Mitsui & Co., Charoen Pokphand Group and EDBI. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mirxes
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mirxes
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mirxes Comparisons
Competitors of Mirxes
Mirxes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UDX and Liquid Mine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-invasive blood-based diagnostics for early cancer detection are developed.
|
|
| domain | founded_year | HQ Location |
Developer of monitoring test system for early detection of leukemia recurrence
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mirxes
Frequently Asked Questions about Mirxes
When was Mirxes founded?
Mirxes was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Mirxes located?
Mirxes is headquartered in Singapore, Singapore.
Is Mirxes a funded company?
Mirxes is a funded company, having raised a total of $254M across 5 funding rounds to date. The company's 1st funding round was a Series C of $77M, raised on Sep 05, 2016.
How many employees does Mirxes have?
As of Dec 31, 2024, the latest employee count at Mirxes is 352.
What is the annual revenue of Mirxes?
Annual revenue of Mirxes is $20.38M as on Dec 31, 2024.
What does Mirxes do?
Developer of miRNA-based test for the detection of cancer. The companys core technology is a highly specific RT-PCR primer that imposes a conformational restriction on miRNA for efficient binding to mature, but not precursor miRNAs, coupled with optimized RT-PCR reagents. These primers confer high specificity, sensitivity, and enhanced signal-to-noise ratio in amplification reactions. The company manufactures miRNA detection and quantification kits for research and is developing miRNA-based liquid biopsy kits for gastric cancer, lung cancer, and breast cancer detection.
Who are the top competitors of Mirxes?
Mirxes's top competitors include UDX and Liquid Mine.
What products or services does Mirxes offer?
Mirxes offers GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite.
Is Mirxes publicly traded?
Yes, Mirxes is publicly traded on HKEX under the ticker symbol 2629.
Who are Mirxes's investors?
Mirxes has 12 investors. Key investors include Mitsui & Co., Charoen Pokphand Group, EDBI, NHH Ventures, and Rock Springs Capital.
What is Mirxes's ticker symbol?
The ticker symbol of Mirxes is 2629 on HKEX.
What is Mirxes's valuation?
The valuation of Mirxes is $500M as of Jul 2021.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.